Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial.
about
Exploring the role and function of trial steering committees: results of an expert panel meetingOptimising recruitment and informed consent in randomised controlled trials: the development and implementation of the Quintet Recruitment Intervention (QRI).Role of information in preparing men for transrectal ultrasound guided prostate biopsy: a qualitative study embedded in the ProtecT trial.Post-diagnosis serum insulin-like growth factors in relation to dietary and lifestyle changes in the Prostate testing for cancer and Treatment (ProtecT) trial.The Memorial Sloan Kettering Cancer Center Recommendations for Prostate Cancer Screening.Prostate-specific antigen-based screening: controversy and guidelinesImplications of polygenic risk-stratified screening for prostate cancer on overdiagnosis.Incorporating Known Genetic Variants Does Not Improve the Accuracy of PSA Testing to Identify High Risk Prostate Cancer on Biopsy.Prospective quality-of-life outcomes for low-risk prostate cancer: Active surveillance versus radical prostatectomy.Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study.Symptomatic and quality-of-life outcomes after treatment for clinically localised prostate cancer: a systematic review.Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study.Establishing nurse-led active surveillance for men with localised prostate cancer: development and formative evaluation of a model of care in the ProtecT trial.Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canary-Early Detection Research Network Active Surveillance Biopsy Risk CalculatorA Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community CohortPhysical activity, alcohol consumption, BMI and smoking status before and after prostate cancer diagnosis in the ProtecT trial: opportunities for lifestyle modification.Insertion of an SVA-E retrotransposon into the CASP8 gene is associated with protection against prostate cancer.Pubertal development and prostate cancer risk: Mendelian randomization study in a population-based cohort.The Treatment of Localized Prostate Cancer in Everyday Practice in GermanyContemporary accuracy of death certificates for coding prostate cancer as a cause of death: Is reliance on death certification good enough? A comparison with blinded review by an independent cause of death evaluation committeeCharacteristics of men responding to an invitation to undergo testing for prostate cancer as part of a randomised trial.Investigating the prostate specific antigen, body mass index and age relationship: is an age-BMI-adjusted PSA model clinically useful?Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life.Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate CancerProstate cancer risk related to foods, food groups, macronutrients and micronutrients derived from the UK Dietary Cohort Consortium food diaries.Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial.Brachytherapy: where has it gone?The evolution of cancer surgery and future perspectives.Organ-confined prostate cancer: are we moving towards more or less radical surgical intervention?The future of trials in surgical oncology.Expectant management for men with early stage prostate cancer.Validation of the Hospital Episode Statistics Outpatient Dataset in England.Multigene panels in prostate cancer risk assessment: a systematic review.Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance.Low serum testosterone predicts upgrading and upstaging of prostate cancer after radical prostatectomy.Unification of favourable intermediate-, unfavourable intermediate-, and very high-risk stratification criteria for prostate cancer.A population-based analysis of contemporary patterns of care in younger men (<60 years old) with localized prostate cancer.Race and mortality risk after radiation therapy in men treated with or without androgen-suppression therapy for favorable-risk prostate cancer.Design of the North Carolina Prostate Cancer Comparative Effectiveness and Survivorship Study (NC ProCESS).Treatment Preferences for Active Surveillance versus Active Treatment among Men with Low-Risk Prostate Cancer.
P2860
Q27007835-21408B18-EF2B-440B-824D-41BBDA0E0C92Q27333751-CB04EF89-F0D1-49C4-8196-D21E20FD1EB0Q30625083-623AADFD-9740-4485-AC3F-DD694B4D24B3Q33885178-D2F3281C-1EA5-49F3-8709-5177D2AC7C69Q34512629-F96DAB5B-14ED-4651-BB40-A5EA02DD5C65Q35211931-5783E7FD-13D3-4B0E-9A05-A50F3ABFA53DQ35602297-6C1523C7-2533-4E8C-B04D-F7661F82C0B7Q35796865-5D33DCCE-058D-4EEC-B1DA-FE255619DEA7Q35812145-2828AC63-9E71-4CAB-8F4A-28107D6C34EBQ35832798-B05BC4C6-B3DE-4A49-B657-CFF3283B8FF0Q35992097-2E18FA90-20B0-4D60-8747-BBE71AD5EF76Q36009824-01149495-EFF6-4BAC-86D6-E2DEFE138291Q36081080-9C386344-B2EE-4485-BBFF-DE1DF6F31F6FQ36093723-AE0E1F18-7898-4FF0-9E1A-5ACE76D74B17Q36275998-64CD6B84-36B6-4CCF-AE69-821A0B3828A3Q36354580-B9CE960F-51B7-404A-9746-B7861DF7DF3DQ36581398-463B9BB0-D16A-41FE-98FA-48345F32F5B8Q36765569-2D941499-9AE5-4D47-A7E6-578DBD3ABB3FQ36996753-B7FF5A18-EAE6-468E-A1E3-15A9F86B997CQ37061367-B8B6AFD6-B14D-4694-A497-BD089215684BQ37340801-2A3D3EFA-D1DD-4DA3-A286-9429A36E5FFCQ37413543-CA7910AB-FF45-41D5-A9ED-3A49F5839C6DQ37420446-51B698C5-71A3-4620-9EF4-B4E47D2EC11FQ37468498-E8E253BC-5141-431F-81F2-5879846C5634Q37560094-1D32EDAD-25E3-4173-AC35-C2C6E1D9C921Q37621409-9B15AF58-E664-46B4-A493-4C8F7D791738Q37658906-3D52A31F-1AB0-46A8-8AF4-45FAF3DE7B19Q38266722-84C232C1-8F79-4324-9E92-4C1B07B98568Q38379151-92D497BE-6205-41AA-A41B-486EBFA0F3BEQ38419183-BFB72F04-255E-4B95-AF64-B038EB42F892Q38469754-5FCB0352-9AC1-4FEA-96D0-847425FF47E0Q38589645-1CE9FC54-C356-4732-88EB-A84CE7791F73Q38596777-FEAA32AF-0E2B-488D-8904-501D56661B69Q39531223-11BCA077-A364-4ADA-88F9-28C5311F2F65Q40144303-9D394D2B-F4C1-44AB-9CF1-C4904C9CDE6AQ40218591-0B432288-1F03-4E97-96F0-5D6932FDCFDEQ40584866-E3CB3ACD-60F0-408D-A9C1-A00F8C07A264Q40636362-ABBEECA6-8916-48BB-B5B1-AC608AF65C00Q41615282-6A4F9A24-2F0B-4160-9433-D04259B77F22Q42265374-6CEE2814-8722-4E5B-AA41-07B3E176CB90
P2860
Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Active monitoring, radical pro ...... tecT randomised phase 3 trial.
@en
Active monitoring, radical pro ...... tecT randomised phase 3 trial.
@nl
type
label
Active monitoring, radical pro ...... tecT randomised phase 3 trial.
@en
Active monitoring, radical pro ...... tecT randomised phase 3 trial.
@nl
prefLabel
Active monitoring, radical pro ...... tecT randomised phase 3 trial.
@en
Active monitoring, radical pro ...... tecT randomised phase 3 trial.
@nl
P2093
P50
P921
P1433
P1476
Active monitoring, radical pro ...... tecT randomised phase 3 trial.
@en
P2093
Chris Metcalfe
Daniel Dedman
Freddie C Hamdy
J Athene Lane
Jenny L Donovan
Malcolm D Mason
Michael Davis
ProtecT study group
P304
P356
10.1016/S1470-2045(14)70361-4
P577
2014-08-19T00:00:00Z